8-Bromo-3-Methylxanthine CAS 93703-24-3 Linagliptin Intermediate Purity ≥99.0% Factory

Chemical Name: 8-Bromo-3-Methylxanthine  CAS: 93703-24-3 Purity: ≥99.0% Appearance: White to Light Yellow Powder Intermediate for Linagliptin (CAS: 668270-12-0) for the treatment type II diabetes mellitus High Quality, Commercial Production E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer Supply Linagliptin and Related Intermediates: Linagliptin CAS 668270-12-0 Linagliptin Parent Nucleus Intermediate CAS 853029-57-9 8-Bromo-3-Methylxanthine CAS 93703-24-3 8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4 2-(Chloromethyl)-4-Methylquinazoline CAS 109113-72-6 (R)-3-(Boc-Amino)piperidine CAS 309956-78-3 (R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4 1-Bromo-2-Butyne CAS 3355-28-0
Item Specifications
Appearance White to Light Yellow Powder
Purity ≥99.0% 
Loss on Drying ≤0.50%
Residue on Ignition ≤0.50%
Single Impurity ≤0.50%
Total Impurities ≤1.0%
Heavy Metals ≤20ppm
Test Standard Enterprise Standard
Usage Intermediate for Linagliptin (CAS: 668270-12-0)

Description:

Specifications:

Package & Storage:

Chemical Name 8-Bromo-3-Methylxanthine
Synonyms 8-Bromo-3-Methyl-3,7-dihydro-1H-purine-2,6-dione
CAS Number 93703-24-3
CAT Number RF-PI501
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C6H5BrN4O2
Molecular Weight 245.03
Melting Point  300℃(lit.)
Density  1.974g/cm3
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

8-Bromo-3-Methylxanthine (CAS: 93703-24-3) is a substituted derivative of of Xanthine. It can be used for the synthesis of Linagliptin (CAS: 668270-12-0), which is a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes. It was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise.Originator is Boehringer Ingelheim (United States).

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours